Affichage 1 à 10 des 12 essais cliniques
ESSAI CLINIQUE
    No essai
    ClinicalTrials.gov ID
Investigateur(trice) principal(e)
Coordonnateur(rice)
(EN) A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer.
    TIGOS
    NCT06646276
     Actif en recrutement
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI  

Poumon à petites cellules Dr Marc Trudeau

Sabrina Côté
  418-541-1000 poste 3065
(EN) A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
    CA244-0001
    NCT06618287
     Actif en recrutement
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Poumon à petites cellules
Poumon non à petites cellules
Dre Marie Florescu

(EN) A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
    CAAA601A42101
    NCT05142696
     Actif en recrutement
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Poumon à petites cellules Dr Daniel Juneau

Adeline Hamon
  514-890-8000 poste 30737
(EN) A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
    CAAA601A42101
    NCT05142696
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Poumon à petites cellules Dre Jennifer Friedmann

Martha Elbebawy
  514-340-8222 poste 28224
(EN) MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
    BRC.8 / SWOG S1827 (MAVERICK)
    NCT04155034
     Actif en recrutement
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT  

Poumon à petites cellules Dre Guy-Anne Turgeon

Patricia Roy
  819-346-1110 poste 14082
(EN) MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
    BRC.8 / SWOG S1827 (MAVERICK)
    NCT04155034
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO  

Poumon à petites cellules Dre Caroline Lavoie

Josée Allard
  418-525-4444 poste 16730
(EN) A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab
    DeLLphi-305
    NCT06211036
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS  

Poumon à petites cellules Dr Nicolas Marcoux

Maryse Gingras
  418-525-4444 poste 15781
(EN) A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer.
    TIGOS
    NCT06646276
     Actif en recrutement
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI  

Poumon à petites cellules Dr Samuel Nadeau

Marie-Eve Fournier
  418-724-3000 poste 8029
(EN) MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
    BRC.8 / SWOG S1827 (MAVERICK)
    NCT04155034
     Actif en recrutement
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR  

Poumon à petites cellules Dr François Vincent

Marie-Ève Caron
  819-697-3333 poste 63238
(EN) A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy
    MK-3475-B98/KEYNOTE-B98
    NCT04938817
     Actif en recrutement
CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL
CENTRE HOSPITALIER DE ST. MARY

Poumon à petites cellules Dr Adrian Langleben

Rachelle Dumas
  514-345-3511 poste 3378